BIIB•benzinga•
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Summary
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025, before final recommendations are issued.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga